Tibet Rhodiola Pharmaceutical guarantees subsidiary's bank facilities

Tibet Rhodiola Pharmaceutical Holding Co., Ltd. (the Company) announced it will provide guarantees totaling 160 million yuan for its wholly-owned subsidiary, Tibet Nordic Pharmaceutical Biomedical Sales Co., Ltd. (Biomedical). This guarantee supports Biomedical's comprehensive credit facilities with Shanghai Pudong Development Bank and Industrial Bank Co., Ltd., each facility amounting to 80 million yuan, with Biomedical providing counter-guarantees to the Company.

As of the announcement date, the Company has extended actual guarantees totaling 378.8029 million yuan to Biomedical. The total outstanding external guarantees by the Company and its holding subsidiaries, all attributed to its holding subsidiaries, amount to 728.8029 million yuan. This represents 18.44% of the Company's net assets from the latest audited period. The guarantees are part of a broader 800 million yuan credit line for holding subsidiaries, approved at the 2024 annual general meeting.

The Company confirmed that all necessary internal approval procedures have been met for these guarantees. Biomedical, the guaranteed entity, maintains a strong financial position, with total assets of 656.4789 million yuan and a net asset value of 170.3319 million yuan as of the first half of 2025 (unaudited), demonstrating robust solvency.